Payment overview · 2025
General Payments
$5,397.26
245 reported records · 34 companies
Healthcare provider profile · identity verified
Hunter Austin Johnson, DO
Allopathic & Osteopathic Physicians|Family Medicine · ANTIOCH, TN · NPI 1295230183
Verified facts
What the public records show
CMS Open Payments records show Hunter Austin Johnson, DO received $5,397.26 in general payments during 2025 across 245 reported records.
Novo Nordisk Inc accounted for 15.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 54 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $829.25 | 15.4% | 33 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $507.12 | 9.4% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $453.26 | 8.4% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $401.81 | 7.4% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $355.09 | 6.6% | 24 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $203.22 | 3.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $201.20 | 3.7% | 10 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $196.87 | 3.6% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $186.85 | 3.5% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $185.09 | 3.4% | 14 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $177.49 | 3.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $173.13 | 3.2% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $171.31 | 3.2% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $154.12 | 2.9% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $143.98 | 2.7% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $142.38 | 2.6% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $138.11 | 2.6% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $137.95 | 2.6% | 5 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $77.42 | 1.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $63.64 | 1.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.52 | 1.1% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $54.59 | 1.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.51 | 0.9% | 3 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $49.87 | 0.9% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $46.38 | 0.9% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $38.74 | 0.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $31.06 | 0.6% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $29.70 | 0.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $29.29 | 0.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.25 | 0.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.86 | 0.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.78 | 0.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.25 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.17 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,397.26 | 245 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $404.15 | 19 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $326.99 | 13 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $275.69 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $265.79 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $221.11 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $213.24 | 10 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $196.87 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $194.90 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $193.60 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $192.22 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $192.22 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $186.85 | 10 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $180.13 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $177.59 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $177.59 | 8 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $177.49 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $162.87 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $153.95 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $143.98 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $142.38 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $138.11 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $137.95 | 5 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $130.53 | 7 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $106.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $104.84 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $100.85 | 7 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $99.79 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $89.25 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $85.26 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $78.22 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $77.42 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.34 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.64 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.51 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $50.51 | 3 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $49.87 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $46.38 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $38.74 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $31.06 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.01 | 3 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $25.27 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.61 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.61 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.61 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 188 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 135 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 96 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
188 | 54 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
96 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
135 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
60 | 21 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 95 |
| Lisinopril | Lisinopril | 294 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 196 | 47 |
| Losartan Potassium | Losartan Potassium | 194 | 73 |
| Farxiga | Dapagliflozin Propanediol | 188 | 54 |
| Metformin Hcl Er | Metformin Hcl | 161 | 55 |
| Metformin Hcl | Metformin Hcl | 154 | 58 |
| Nifedipine Er | Nifedipine | 144 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 138 | 44 |
| Ozempic | Semaglutide | 135 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 124 | 53 |
| Omeprazole | Omeprazole | 119 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 35 |
| Famotidine | Famotidine | 99 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 33 |
| Trazodone Hcl | Trazodone Hcl | 98 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 38 |
| Carvedilol | Carvedilol | 86 | 25 |
| Prednisone | Prednisone | 85 | 52 |
| Jardiance | Empagliflozin | 83 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 24 |
| Sertraline Hcl | Sertraline Hcl | 62 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 22 |
| Rybelsus | Semaglutide | 60 | 21 |
| Furosemide | Furosemide | 59 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 18 |
| Alendronate Sodium | Alendronate Sodium | 54 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 15 |
| Azithromycin | Azithromycin | 49 | 38 |
| Kerendia | Finerenone | 47 | 13 |
| Meloxicam | Meloxicam | 46 | 22 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Gabapentin | Gabapentin | 43 | 16 |
| Spironolactone | Spironolactone | 43 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Allopurinol | Allopurinol | 41 | 13 |
| Buspirone Hcl | Buspirone Hcl | 38 | 11 |
| Celecoxib | Celecoxib | 38 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 13 |
| Ezetimibe | Ezetimibe | 37 | 17 |
| Simvastatin | Simvastatin | 37 | 11 |
| Chlorthalidone | Chlorthalidone | 35 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 19 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 21 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Gemtesa | Vibegron | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | 12 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,397.26 · 245 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AFREZZA, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FASENRA, GARDASIL 9, GEMTESA, Heplisav-B, INGREZZA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, Wegovy, XIFAXAN, Xhance, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error